explore -WSS

explore

author：leisure time 2025-09-06 04:41:08 - browse：4

Japanese drugmaker Eisai said Tuesday that Ivan Cheung, chairman of its U.S. operations and global head of its Alzheimer’s disease unit, will retire at the end of the month. The surprise announcement comes just days after Eisai won final approval in the U.S. for its Alzheimer’s drug Leqembi.

Cheung will be replaced in his capacity as head of the Alzheimer’s unit by his brother-in-law Keisuke Naito, 34, who is currently chief ecosystem officer and chief strategy officer. He is also the son of Eisai CEO Haruo Naito.

Tatsuyuki Yasuno, current chief financial officer, will replace Cheung as head of Eisai’s U.S. unit.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Philips to halt sales of sleep apnea machines in U.S.

WSS

White House pharmacy plagued with problems, investigation finds

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

Medicare Advantage overpayments discussion gets experts fired up

FDA early review: GLP

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

Nonprofit, backed by Microsoft, to certify AI tools in health care

hotspot

explore

hotspot

Anesthesiologist group: stop taking Ozempic before surgery

Male doctors called my cancer incurable. A female doctor showed it wasn't

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Male doctors called my cancer incurable. A female doctor showed it wasn't

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Allen Institute goes after foundational questions, CEO Costa says

How one medical school became remarkably diverse

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Drug repurposing or repositioning? The language matters

Merck CEO won’t testify in Senate, citing no expertise in drug prices

focus

American taxpayers paid $1.8 trillion in health care costs in 2022

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

How generative AI ratchets up security threats for health systems

Biogen walks away from Aduhelm, years after polarizing approval

Zyn nicotine pouches become unlikely player in latest culture war

The Affordable Care Act has saved billions in health care costs

hotspot

Wikipedia

entertainment

explore